Melatonin receptors play important roles in the regulation of circadian and seasonal rhythms, sleep, retinal functions, the immune system, depression, and type 2 diabetes development. Melatonin receptors are approved drug targets for insomnia, non-24-hour sleep-wake disorders, and major depressive disorders. In mammals, two melatonin receptors (MTRs) exist, MT 1 and MT 2 , belonging to the G protein-coupled receptor (GPCR) superfamily. Similar to most other GPCRs, reliable antibodies recognizing melatonin receptors proved to be difficult to obtain. Here, we describe the development of the first monoclonal antibodies (mABs) for mouse MT 1 and MT 2 .
| INTRODUCTION
Melatonin receptors belong to the G protein-coupled receptor superfamily, which preferentially couple to Gα i/o proteins. 1 The melatonin receptor (MTR) subfamily is composed of three members in mammals: MT 1 and MT 2 , which are both binding to the neurohormone melatonin with high affinity, 2 and GPR50, which has 70% sequence homology with MT 1 and MT 2 but lost the capacity to bind melatonin during evolution due to modifications in the second extracellular loop. 3, 4 MT 1 and MT 2 are involved in various biological functions including the regulation of biological rhythms, sleep, pain, retinal, neuronal, and immune functions. 1, 5 Melatonin receptor-knockout mice show deficits in many of these functions. 6 Alteration of MTR function or expression in humans is associated with depression, 7 Alzheimer's disease, [8] [9] [10] and type 2 diabetes.
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To study the function of proteins and to discriminate between closely related subtypes like MT 1 and MT 2 , antibodies are indispensable tools. Yet, reliable and specific antibodies recognizing GPCRs are notoriously difficult to obtain. Unfortunately, this is also the case for MT 1 and MT 2 . GPR50 escaped from this rule since its long carboxyl-terminal domain facilitated the successful generation of highly specific and sensitive antibodies, 12 which boosted progress in its study. 13, 14 In the case of MT 1 and MT 2 , low expression levels typically observed in tissues render their detection even more difficult. 15 Currently available antibodies include the 536-antibody from our laboratory recognizing specifically the recombinant and endogenously expressed human MT 1 7,10,16-23 but neither the human MT 2 nor the mouse, rat, or hamster MT 1 (personal communication RJ) and two antibodies from the Fraschini laboratory. [7] [8] [9] [23] [24] [25] [26] These were generated against the human MT 1 and MT 2 and cross-react with rat but not with the mouse receptors. Other, commercially available, antibodies are poorly characterized, and key data for them are generally unavailable, such as their detection of recombinant MTRs or immunoreactivity (IR) with established tissues of melatonin receptor expression in wild-type and in MTR-knockout mice as a control. Moreover, all validated antibodies directed against MTRs are polyclonal generated in rabbits, and none of them reacts with the mouse MTRs. Hence, more anti-MTR antibodies are necessary, especially against those of murine origin. Taking into account that the vast majority of studies on melatonin effects are conducted in mice, reliable antibodies against mice MTRs are of urgent need. We therefore decided to develop monoclonal antibodies (mABs) for mouse MT 1 and MT 2 using their C-terminal regions fused to glutathione-S-transferase (GST) as immunogen.
| MATERIAL AND METHODS

| Design and production of GST fusion proteins
Glutathione-S-transferase (GST) fusion proteins composed of GST fused at its carboxyl-terminus with the cytoplasmic domains of the mouse MT 1 (amino acid residues 302-353) (GST-mMT 1 Cter) or MT 2 (amino acids 312-364) (GST-mMT 2 Cter) were constructed. GST constructs were expressed in Escherichia coli and purified on immobilized glutathione according to standard protocols.
| Generation of monoclonal antibodies
A 1:1 mixture of GST-mMT 1 Cter and GST-mMT 2 Cter fusion proteins (25 µg total amount) was used for immunization of 5 BALB/c mice. Standard PEG fusions with splenocytes harvested from the three mice with the strongest immune response yielded a total of 28 hybridoma cell lines that were specific for either MT 1 or MT 2 . Primary screening was done in a multiplex assay format using the Meso Scale Discovery (MSD) electrochemiluminescence platform. Each hybridoma clone was simultaneously assayed on the injected GSTmMT 1 Cter and GST-mMT 2 Cter fusion proteins, as well as on free GST and a non-related GST-fused protein to eliminate GST-reactive clones. Selected clones were subcloned, and antibodies were purified from hybridoma supernatant using HiTrap Protein G columns (GE Healthcare). Five of the seven clones with a positive signal, namely mAB-A06, mAB-A84, mAB-H04, mAB-J50, and mAB-I81, were further characterized. 
| SDS-PAGE and western blotting
Forty-eight hours post-transfection, HEK293T cells expressing mouse, human, or rat MTRs were collected into lysis buffer (62.5 mmol/L Tris/HCl pH 6.8, 5% SDS, 10% glycerol, 0.005% bromophenol blue), as previously described.
32
Brain tissues were removed and immediately processed for preparation of crude membranes. Briefly, tissues were homogenized using a Polytron homogenizer in TEM buffer (75 mmol/L Tris pH7.5; 5 mmol/L EDTA; 12.5 mmol/L MgCl 2 ), followed by ultracentrifugation (51 500× g, 45 minutes), and the remaining pellet was resuspended in TE buffer (75 mmol/L Tris pH7.5; 5 mmol/L EDTA). Denatured proteins were resolved in 10% SDS-PAGE gels, transferred to nitrocellulose membranes, and immunoblotted using the mABs (2 µg/mL) or the polyclonal rabbit anti-FLAG or anti-MYC antibodies. Immunoreactivity is revealed using secondary antibodies coupled to 680-or 800-nm fluorophores (LI-COR Biosciences, Lincoln, NE, USA), and membranes were read in the Odyssey LI-COR infrared fluorescent scanner (LI-COR Biosciences).
| Immunofluorescence microscopy
Tissues from WT and MT 1 -/MT 2 -KO mice were collected in the morning, at Zeitgeber time (ZT) 3 hours (ZT is defined relative to the light cycle, with ZT0 representing the time lights are turned on, and ZT12 = lights off), as this was the time with maximum melatonin-binding sites detected in the hypothalamic suprachiasmatic nucleus of mice. 33 Mice were anesthetized (ketamine/xylazine solution; 100-10 mg/kg) and perfused with 0.9% saline followed by 4% paraformaldehyde (PFA), and the brain and eyeballs were collected, post-fixed in 4% PFA (24 hours, 4°C), and cryoprotected in 30% sucrose solution (24 hours, 4°C). Tissues were included in freezing OCT medium (Tissue-Tek), snap frozen, and kept at −80°C until processed in the cryostat (CM350S, Leica) to obtain 10 µm thick sections. Immunofluorescence analysis was also performed in HEK293T cells expressing MTRs. Forty-eight hours post-transfection, cells were fixed in 2% PFA (15 minutes, −20°C) and permeabilized with Triton X-100 (0.2%, 1 hour), as described. 34 Tissue slice and fixed cells were blocked with horse serum and incubated with mABs (10 µg/mL, overnight, 4°C), followed by incubation with anti-TAG antibodies (anti-FLAG 1:500, Sigma-Aldrich; anti-MYC (1:500, Santa Cruz Biotechnology) or anti-BIP (endoplasmic reticulum marker; 1:3000, Sigma-Aldrich) antibody and the secondary antibodies Alexa Fluor 555 anti-mouse and Alexa Fluor 647 anti-rabbit (1:200, 2 hours, RT). DAPI (1:3000, 5 minutes; Santa Cruz Biotechnology) was used to stain the cell nuclei. Insulin was detected with a guinea pig anti-insulin antibody (1:200; DAKO, Glostrup, Denmark) followed by a goat anti-guinea pig IgG conjugated to Alexa Fluor 568 (1:200; Molecular Probes #A11075, Eugene, OR, USA). The slides were mounted and analyzed by fluorescence confocal microscopy (Axion, Carl Zeiss, Jena, Germany; Leica DMI600 spinning disk CSU-X1M1) or by slide scanner (Lamina, Perkin Elmer). Images were analyzed using ImageJ software (National Institutes of Health, USA).
| Proximity ligation assay (PLA)
Transfected HEK293T cells, plated onto glass coverslips, were fixed with 4% PFA for 15 minutes (RT). Fixed cells were permeabilized with 0.2% Triton X-100 for 10 minutes, followed by blocking in PBS containing 3% BSA (1 hour, RT). Cells were incubated with mABs A06 or A84 (1 μg/ mL) or mouse anti-FLAG (1:1000, Sigma-Aldrich) or mouse anti-MYC (1:1000, Santa Cruz Biotechnology) and goat anti-5HT 2C (1:100, Santa Cruz Biotechnology) antibodies overnight at 4°C. PLA was conducted using Duolink® In Situ-Fluorescence kit (Sigma-Aldrich), following the instructions of the manufacturer. Images were captured using a confocal microscope and analyzed with ImageJ software (NIH, Bethesda).
| Immunoprecipitation
Crude membranes were prepared from HEK293T cells transiently expressing mMT 1 or mMT 2 labeled with 2-
iodo-melatonin (400 pmol/L) (PerkinElmer, Life Sciences) as described. 35 Labeled receptors were solubilized with 1% digitonin, a detergent known to maintain melatonin receptors in a native conformation, and cleared lysates incubated with purified mABs (1 µg/mL) overnight at 4°C as previously described. 8 
| RESULTS AND DISCUSSION
To obtain mABs against mMT 1 and mMT 2 , we expressed in E coli carboxyl-terminal GST fusion proteins containing the 52 or 53 C-terminal amino acids of mouse MT 1 and MT 2 (GST-mMT 1 Cter and GST-mMT 2 Cter), respectively, which show 23% sequence homology ( Figure 1A ). Mice were immunized with the purified fusion proteins. Out of 28 hybridoma cell lines obtained, clones A06, A84, H04, J50, and I81 were retained for further evaluation based on their ability to produce mABs recognizing either GST-mMT 1 Cter and GST-mMT 2 Cter, but not GST alone by using the Meso Scale Discovery (MSD) technology platform ( Figure S1 ). The reactivity of the five selected mABs was then tested by Western blot (WB) in whole-cell lysates of HEK293T cells expressing, or not, epitope-tagged mMT 1 or mMT 2 ( Figures  2 and 3) . mAB-A06 and mAB-J50 recognized mMT 1 but did not show any IR toward lysates of non-transfected cells or cells expressing mMT 2 (Figure 2A,B) . Both mABs and the anti-TAG antibody recognized immunoreactive bands with apparent molecular weights of about 50 and 110 kDa, which most likely correspond to the monomeric and dimeric forms of mMT 1 . Further bands migrated at high molecular weights and most likely correspond to receptor oligomers. mAB-A06 recognized also hMT 1 with a similar monomer/dimer pattern as the anti-TAG antibody ( Figure 2C ). There was no crossreactivity with rMT 1 ( Figure 2D ). mAB-A84, mAB-H04, and mAB-I81 readily recognized mMT 2 but did not show any IR against lysates of non-transfected cells or cells expressing mMT 1 ( Figure  3A ,B). All three mABs and the anti-TAG antibody consistently recognized a doublet band in the range of 55-65 kDa and another broadband at 100-120 kDa corresponding most likely to different monomeric and dimeric receptor species, respectively. Additional high molecular weight oligomeric receptor forms were also detected. hMT 2 and rMT 2 were not recognized by any of the three mABs ( Figure 3C,D) . Collectively, these are the first antibodies which specifically recognize either recombinant SDS-denatured mMT 1 or mMT 2 by WB. mAB-A06 recognizes also the hMT 1 receptor, which has 73% (38/52 residues) sequence homology with the mMT 1 -Cter ( Figure 1B) .
We next performed confocal immunofluorescence (IF) microscopy experiments in fixed and Triton X-100 permeabilized HEK293T cells expressing, or not, epitope-tagged MT 1 or MT 2 (Figures 4 and 5) . Co-staining of cells with anti-TAG antibodies and mAB-A06 or mAB-J50 showed similar labeling in intracellular compartments and at the cell surface expressing mMT 1 but no staining of non-transfected cells in the same frame ( Figure 4A,B) . Both mABs did not immunolabel cells expressing mMT 2 ( Figure 4B ).
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Immunofluorescence microscopy analysis of mAB-A06 and mAB-J50 with recombinant melatonin receptors. Fixed HEK293T cells expressing epitope-tagged mMT 1 (A), mMT 2 (B), hMT 1 (C), rMT 1 (D) or hMT 2 (E) were incubated with mAB-A06 and mAB-J50, followed by incubation with anti-TAG antibodies, and analyzed by confocal immunofluorescence microscopy. The cell nuclei are stained with DAPI (blue). Scale bar: 10 µm Cells expressing hMT 1 were stained with both mABs, whereas cells expressing rMT 1 were negative in both cases ( Figure 4C,D) . The IR to human receptors revealed to be specific, as virtually no IR was detected in hMT 2 -expressing cells ( Figure 4E ). In cells expressing mMT 2 , mAB-A84, mAB-H04, and mAB-I81 all showed positive IR at the cell membrane and intracellular compartments, which was superimposable with the IR detected with the anti-TAG antibodies ( Figure 5A ). No staining was observed in nontransfected cells in the same frame ( Figure 5A ) or in cells expressing mMT 1 ( Figure 5B ). Cells expressing hMT 2 were immunostained with mAB-A84 and mAB-I81 ( Figure 5C ), while cells expressing rMT 2 or hMT 1 were negative for all three mABs ( Figure 5D,E) . Taken together, the mABs recognized specifically either recombinant mMT 1 or mMT 2 by immunofluorescence microscopy at the cellular level with a comparable pattern to anti-TAG antibodies. mAB-A06 and mAB-J50 cross-reacted with hMT 1 ( Figure 1B ) and mAB-A84 and mAB-I81 with the hMT 2 ( Figure 1C) . None of the mABs cross-reacted with the rat receptors. In order
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Immunofluorescence microscopy analysis of mAB-A84, mAB-H04, and mAB-I81 with recombinant melatonin receptors. Fixed HEK293T cells expressing epitope-tagged mMT 2 (A), mMT 1 (B), hMT 2 (C), rMT 2 (D), or hMT 1 (E) were incubated with mAB-A84, mAB-H04, and mAB-I81, followed by incubation with anti-TAG antibodies, and analyzed by confocal immunofluorescence microscopy. The cell nuclei are stained with DAPI (blue). Scale bar: 10 µm
to analyze the subcellular distribution of mMTRs, higher magnitude images were taken and analyzed by co-localization with the endoplasmic reticulum (ER) marker, BIP. As shown in Figure 6 , few co-localization of mMTRs with the ER is observed, as the majority of receptors are located at the plasma membrane.
The proximity ligation assay (PLA) is increasingly applied to detect proximity between two proteins at the cellular level in a sensitive manner. To verify the compatibility of the mABs with this technique, we probed the proximity between the serotonin m5-HT 2C receptor and mMT 1 or mMT 2 , two heterodimers that have been recently described. 37 Positive PLA signals were observed between the mMT 1 -specific mAB-A06 and anti-5-HT 2C antibodies in HEK293T cells co-expressing mMT 1 and m5-HT 2C receptors but not in mock-transfected cells ( Figure 7A , left and middle panel). Anti-FLAG antibodies were used as positive control ( Figure 7A, right panel) . Similarly, positive PLA signals were detected between the MT 2 -specific mAB-A84 and anti-5-HT 2C antibodies in HEK293T cells co-expressing mMT 2 and m5-HT 2C receptors but not in mock-transfected cells ( Figure 7B , left and middle panel). Anti-MYC antibodies were here used as positive control ( Figure 7B, right panel) . The number of PLA signals was comparable to those reported for other GPCR heterodimeric complexes. 38, 39 The lower staining observed for the MT 1 /5-HT 2C dimer compared to MT 2 /5-HT 2C might be explained by the higher BRET 50 value (lower propensity to form dimers) of the former, as previously reported. 37 Collectively, mAB-A06 and mAB-A84 are able to detect heterodimeric complexes involving mMT 1 or mMT 2 , respectively. To verify whether the mABs are able to immunoprecipitate native mMT 1 and mMT 2 independently expressed in HEK293T cells, we first labeled them with the specific radioligand 2-[
125 I]iodo-melatonin and then solubilized them with digitonin. Lysates were incubated with mABs, immunocomplexes precipitated with protein A-agarose beads and the amount of the radioactively labeled receptor in precipitates determined. mAB-A06 or mAB-J50 precipitated around 8% of the labeled mMT 1 receptor, which is higher than the amount precipitated by the anti-FLAG antibody. mAB-A84, mAB-H04, mAB-I81, and anti-MYC precipitated between 12% and 18% of the labeled mMT 2 receptor ( Figure 8A,B) . Neglectable signals were observed with non-relevant control IgGs, confirming the specificity of the assay ( Figure 8A ,B,
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Immunofluorescence microscopy analysis of subcellular localization of recombinant melatonin receptors. Fixed HEK293T cells expressing mMT 1 (A) or mMT 2 (B) were incubated with mAB-A06 (A) or mAB-H04 (B), followed by incubation with anti-BIP antibody (ER marker), and analyzed by confocal immunofluorescence microscopy. The cell nuclei are stained with DAPI (blue). Open white arrowheads indicate absence of co-localization; closed white arrowheads indicate co-localization. Scale bar: 10 µm background). These data show that the mABs recognize the native, digitonin-solubilized melatonin receptors. Because this assay was performed in the presence of the ligand, we wondered whether the activation state of the receptor could impact the ability of mABs to recognize the antigen, as they target the C-terminal domain of the receptors which is usually involved in the recruitment of signaling molecules upon activation. Immunoprecipitation assay revealed by WB in activated vs. non-activated cells show that there is no impact of receptor activation on the efficiency of the antibodies in recognizing their target ( Figure 8C,D) . The other way round was also investigated, that is, whether the antibodies could affect the activation of the receptors. G protein activation accessed by [ 35 S]GTPS binding assay revealed no difference on melatonin-induced activation of mMT 1 or mMT 2 in the presence of any mABs ( Figure 8E,F) . We next detected melatonin receptor expression in mouse retina ( Figure 9A ). The IR detected with the MT 1 -specific mAB-A06 and mAB-J50 and with the MT 2 -specific mAB-A84, mAB-H04, and mAB-I81 was restricted to the outer segment, to single cells of the outer plexiform layer (OPL) and to the ganglion cell layer (GCL). Only background F I G U R E 7 Proximity ligation assay with mABs against mMT 1 and mMT 2 to detect heterodimeric complexes with 5-HT 2C receptors. Fixed HEK293T cells co-expressing m5-HT 2C and FLAG-tagged mMT 1 (A) or MYC-tagged mMT 2 (B) were submitted to in situ PLA using mAB-A06 (A) or mAB-A84 (B) together with anti-m5-HT 2C antibodies and analyzed by confocal fluorescence microscopy. Mock-transfected cells were used as negative controls and anti-TAG antibodies as positive controls. The cell nuclei are stained with DAPI (blue). Scale bar: 10 µm staining was observed in MT 1 and MT 2 double-knockout mice (MTR-dKO). These results indicate that our mABs detect endogenously expressed receptors in the mouse retina with an expression pattern in agreement with previous reports. 31, 40 The hypothalamic suprachiasmatic nuclei (SCN) and the pituitary gland are two additional expression sites of MTRs. [41] [42] [43] [44] [45] Immunostaining of both areas with mAB-J50
and mAB-H04 resulted in the labeling of distinct cells in wild-type mice, but not in MTR-dKO mice, which only displayed some background signals ( Figure 9B,C) . Attempts to detect MTRs by WB in lysates of mouse brain regions of reported MTR mRNA expression 1 (cerebellum, hippocampus, hypothalamus, striatum, cortex) were instead inconclusive as several candidate bands with similar intensity were detected in wild-type and MTR-dKO mice illustrating the challenge to detect MTRs in lysates of brain regions where these receptors are only expressed in a subset of cells ( Figure S2 ). Genetic variants of the MTNR1B gene encoding MT 2 have been associated with type 2 diabetes risk.
11 Pancreatic beta-cells were proposed to be a main site of MT 2 action involved in the regulation of glucose homeostasis, 46 but this suggestion remains controversial, in part due to difficulties in demonstrating the expression of the MT 2 protein in these cells. 47 For example, in the rat MIN6 beta-cell line melatonininduced cAMP and insulin secretion were reported. 48, 49 RNA sequencing data on the expression levels of MTNR1A and MTNR1B genes coding for MT 1 and MT 2 receptors, respectively, in different beta-pancreatic cell lines including MIN6 cells and mouse and rat islets revealed expression levels close to background levels (Table S1 ). In MIN6 cell lysates, the MT 2 -specific mAB-H04, which does not recognize rat MT 2 , detected bands similar to those detected in the rat INS1 cell line, which was used as negative control ( Figure S3A ). Similarly, we were unable to detect MT 2 expression in MIN6 cells by IF ( Figure S3B ). Furthermore, mAB-H04 did not reveal any specific IR in pancreatic sections of WT and MT 2 -KO mice ( Figure S3C ). Taken together, our data indicate that mouse pancreatic beta-cells do not express amounts of MT 2 that are detectable with our specific anti-MT 2 mAB-H04.
| CONCLUSION
The novel mABs against mMTRs described here specifically recognize either mMT 1 or mMT 2 without any cross-reactivity between the two receptors and will open new venues for their study by enabling the assessment of their protein expression levels in different mouse tissues, which is currently poorly defined by other methods. 1, 50 The expression profile of melatonin receptors at the protein level has been systematically described only in the rat brain 26 and in humans only for specific peripheral and central sites [7] [8] [9] [10] [17] [18] [19] [20] [21] [22] [23] 25 . Due to the expression of receptors in a subset of cells in a given tissue, immunofluorescence and histological methods are expected to be most successful in detecting these receptors in tissues. Further significant advances may result from co-immunostaining of MTRs in human tissues, for example, for detection of MT 1 /MT 2 , MT 2 /5-HT 2C , and MT 1 /GPR50 heterodimers or their co-localization with other cell type-specific antigens.
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